Nanovax
Nanovax’s seasonal flu vaccine meets Phase 3 endpoints and matches Sanofi’s Fluzone
March 24, 2020Manufacturing and Production, Research and Development NanoFlu, Nanovax, influenza, pharma
Nanovax has reported positive Phase 3 data for its vaccine NanoFlu, with the candidate meeting its primary endpoints in the …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
